PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 7769130-5 1995 In addition, testosterone, dihydrotestosterone, and adrenal androgens inhibited the expression of a chloramphenicol acetyl transferase reporter plasmid driven by the human IL-6 promoter in HeLa cells cotransfected with an androgen receptor expression plasmid; however, these steroids were ineffective when the cells were cotransfected with an estrogen receptor expression plasmid. Testosterone 13-25 estrogen receptor 1 Homo sapiens 343-360 33411236-10 2021 In testosterone- treated Wobblers a reduction of AR, ERalpha, and aromatase and high levels of Sigma-1 receptor mRNAs was demonstrated. Testosterone 3-15 estrogen receptor 1 Homo sapiens 53-60 18407221-2 1994 The issue is complicated by the fact that testosterone may act both directly via the androgen receptor and indirectly, after its aromatization to 17beta-estradiol, through the estrogen receptor. Testosterone 42-54 estrogen receptor 1 Homo sapiens 176-193 33771918-5 2021 In the men with GG4 PCa, blocking of adrenal synthesis of testosterone for 2 mo to 7 mo had the beneficial effect of increasing ERbeta expression, but, on treatment longer than 8 mo, ERbeta was lost and EGFR moved to the nucleus. Testosterone 58-70 estrogen receptor 1 Homo sapiens 128-134 33771918-5 2021 In the men with GG4 PCa, blocking of adrenal synthesis of testosterone for 2 mo to 7 mo had the beneficial effect of increasing ERbeta expression, but, on treatment longer than 8 mo, ERbeta was lost and EGFR moved to the nucleus. Testosterone 58-70 estrogen receptor 1 Homo sapiens 183-189 34792618-7 2022 RESULTS: From an initial panel of 822 SNPs, we identified five testosterone-increasing alleles (DOCK3 rs77031559 G, ESR1 rs190930099 G, GLIS3 rs34706136 TG, GRAMD1B rs850294 T, TRAIP rs62260729 C) nominally associated (P < 0.05) with CSA of fast-twitch muscle fibers, fat-free mass and handgrip strength. Testosterone 63-75 estrogen receptor 1 Homo sapiens 116-120 34630328-2 2021 Estrogen, testosterone and progesterone are all considered to interact with the immune system through their respective cell receptors (ERalpha and ERbeta including the splice variant ERbeta2, AR and PGR). Testosterone 10-22 estrogen receptor 1 Homo sapiens 135-142 34630328-2 2021 Estrogen, testosterone and progesterone are all considered to interact with the immune system through their respective cell receptors (ERalpha and ERbeta including the splice variant ERbeta2, AR and PGR). Testosterone 10-22 estrogen receptor 1 Homo sapiens 147-153 35203670-17 2022 Furthermore, estrogen receptor methylation appears to be associated with the age of the subjects and exogenous testosterone administration, representing a marker of androgenic treatment. Testosterone 111-123 estrogen receptor 1 Homo sapiens 13-30 7175103-5 1982 The binding was specific for all three estrogens whereas a 1000-fold excess of progesterone, dihydrotestosterone and testosterone was required in order to obtain competition for the estrogen receptor. Testosterone 100-112 estrogen receptor 1 Homo sapiens 182-199 7428683-2 1980 These studies were initiated to examine the testicular content of cytoplasmic estrogen receptor in relation to hCG-induced desensitization of testosterone production 24 h and 5 days after a sc injection of hCG. Testosterone 142-154 estrogen receptor 1 Homo sapiens 78-95 32255524-0 2020 A case of a trans-masculine patient receiving testosterone with a history of estrogen receptor-positive breast cancer. Testosterone 46-58 estrogen receptor 1 Homo sapiens 77-94 33900852-9 2021 Virilizing concentrations of testosterone down-regulated AR and ESR1 in subcutaneous (sc) WAT and upregulated transcript levels of insulin signaling pathway components in WAT and liver. Testosterone 29-41 estrogen receptor 1 Homo sapiens 64-68 28734725-6 2017 These mutants recapitulate the increased serum testosterone levels seen with constitutive ERalpha deletion, but have none of the behavioral deficits. Testosterone 47-59 estrogen receptor 1 Homo sapiens 90-97 29895278-16 2018 CONCLUSIONS: In ER-positive postmenopausal breast cancer patients, high testosterone levels are associated with worse prognosis in normal-weight and overweight women, whereas in obese seems to be associated with a better outcome. Testosterone 72-84 estrogen receptor 1 Homo sapiens 16-18 29895278-17 2018 Although the results require further validation, they suggest that assessment of circulating testosterone and BMI could help to identify postmenopausal ER-positive patients at higher risk of relapse and potentially open new therapeutic strategies. Testosterone 93-105 estrogen receptor 1 Homo sapiens 152-154 28910727-6 2017 Moreover, the observations indicated that fluoride exposure and genetic markers had an interaction on serum concentration of follicle-stimulating hormone and estradiol, and the interaction among different loci of the ERalpha gene could impact the serum testosterone level. Testosterone 253-265 estrogen receptor 1 Homo sapiens 217-224 32454105-5 2020 We also observed that male and female urogenital sinus (UGS) responded differentially to testosterone treatment, demonstrating heterogeneous immunostaining for the androgen receptor (AR), estrogen receptor alpha (ERalpha), and proliferating cell nuclear antigen (PCNA). Testosterone 89-101 estrogen receptor 1 Homo sapiens 188-211 32454105-5 2020 We also observed that male and female urogenital sinus (UGS) responded differentially to testosterone treatment, demonstrating heterogeneous immunostaining for the androgen receptor (AR), estrogen receptor alpha (ERalpha), and proliferating cell nuclear antigen (PCNA). Testosterone 89-101 estrogen receptor 1 Homo sapiens 213-220 32655040-0 2020 Testosterone Increases Fibroblast Proliferation in vitro Through Androgen and Estrogen Receptor Activation. Testosterone 0-12 estrogen receptor 1 Homo sapiens 78-95 30909145-9 2019 Furthermore, in vitro studies showed a synergistic effect of testosterone and estradiol on GDF-15 secretion, and demonstrated that testosterone association with estradiol decreased GDF-15 secretion through androgen receptor/estrogen receptor-mediated pathways. Testosterone 131-143 estrogen receptor 1 Homo sapiens 224-241 29895278-0 2018 Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients. Testosterone 47-59 estrogen receptor 1 Homo sapiens 92-109 28720108-10 2017 Higher testosterone was positively associated with ER+/PR+ disease risk (ORlog2: 1.57 (1.13-2.18)). Testosterone 7-19 estrogen receptor 1 Homo sapiens 51-53 28720108-14 2017 High circulating testosterone in early pregnancy, which likely reflects nonpregnant premenopausal exposure, was associated with higher risk of ER+/PR+ disease. Testosterone 17-29 estrogen receptor 1 Homo sapiens 143-145 25837259-4 2015 Furthermore, treatment with the aromatase substrate, testosterone, inhibited suspension culture-induced apoptosis whereas an aromatase inhibitor attenuated the effect of testosterone suggesting that suspended circulating ERalpha positive breast cancer cells may up-regulate intracrine estrogen activity for survival. Testosterone 53-65 estrogen receptor 1 Homo sapiens 221-228 28193709-6 2017 In a trophoblast cell line, JEG-3 cells, testosterone repressed the expression of aromatase and estrogen receptor alpha and the production of estradiol while promoting miR-22 expression. Testosterone 41-53 estrogen receptor 1 Homo sapiens 96-119 25837259-4 2015 Furthermore, treatment with the aromatase substrate, testosterone, inhibited suspension culture-induced apoptosis whereas an aromatase inhibitor attenuated the effect of testosterone suggesting that suspended circulating ERalpha positive breast cancer cells may up-regulate intracrine estrogen activity for survival. Testosterone 170-182 estrogen receptor 1 Homo sapiens 221-228 24968970-0 2015 Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer. Testosterone 60-72 estrogen receptor 1 Homo sapiens 10-33 24968970-2 2015 OBJECTIVE: To assess the ability of an oral selective estrogen receptor alpha agonist (GTx-758) to lower testosterone concentrations compared with leuprolide while minimizing estrogen deficiency-related side effects of androgen-deprivation therapy. Testosterone 105-117 estrogen receptor 1 Homo sapiens 54-77 25612679-5 2015 Our results showed that CTet inhibited TE-driven ERalpha phosphorylation of both cytosolic and nuclear ERalpha pools, suggesting an inhibitory effect of TE aromatization in E2. Testosterone 39-41 estrogen receptor 1 Homo sapiens 49-56 25612679-5 2015 Our results showed that CTet inhibited TE-driven ERalpha phosphorylation of both cytosolic and nuclear ERalpha pools, suggesting an inhibitory effect of TE aromatization in E2. Testosterone 39-41 estrogen receptor 1 Homo sapiens 103-110 24995161-1 2014 AKR1C3 is a novel therapeutic target in castration-resistant prostate cancer (CRPC) and estrogen receptor (ER)-positive breast cancer because of its ability to produce testosterone and 17beta-estradiol intratumorally, thus promoting nuclear receptor signaling and tumor progression. Testosterone 168-180 estrogen receptor 1 Homo sapiens 88-105 24995161-1 2014 AKR1C3 is a novel therapeutic target in castration-resistant prostate cancer (CRPC) and estrogen receptor (ER)-positive breast cancer because of its ability to produce testosterone and 17beta-estradiol intratumorally, thus promoting nuclear receptor signaling and tumor progression. Testosterone 168-180 estrogen receptor 1 Homo sapiens 107-109 24385014-3 2014 Testosterone is converted to the superactive androgen dihydrotestosterone and to estradiol, and thus has actions via androgen receptors and both estrogen receptors (ERalpha, ERbeta). Testosterone 0-12 estrogen receptor 1 Homo sapiens 165-172 23506158-6 2013 In individuals with low total (<=11 nmol/L) or free testosterone (<=0.18 nmol/L) being carriers of the variant A-allele in ESR1 was associated with 7.3 and 15.9 times, respectively, increased odds ratio of being diagnosed with diabetes mellitus type 2 (p = 0.025 and p = 0.018, respectively). Testosterone 55-67 estrogen receptor 1 Homo sapiens 129-133 23552580-0 2013 Effects of long-term high dose testosterone administration on vaginal epithelium structure and estrogen receptor-alpha and -beta expression of young women. Testosterone 31-43 estrogen receptor 1 Homo sapiens 95-118 23241075-8 2012 When women defined by ER status were analyzed separately, regression analysis in the ER-positive group showed a significant association of high testosterone levels with AR-highly-positive expression (OR 1.86; 95% CI, 1.10-3.16), but the association was essentially due to patients greater than or equal to 65 years (OR 2.42; 95% CI, 1.22-4.82). Testosterone 144-156 estrogen receptor 1 Homo sapiens 22-24 23584859-0 2013 Estradiol and testosterone regulate arginine-vasopressin expression in SH-SY5Y human female neuroblastoma cells through estrogen receptors-alpha and -beta. Testosterone 14-26 estrogen receptor 1 Homo sapiens 120-154 23241075-8 2012 When women defined by ER status were analyzed separately, regression analysis in the ER-positive group showed a significant association of high testosterone levels with AR-highly-positive expression (OR 1.86; 95% CI, 1.10-3.16), but the association was essentially due to patients greater than or equal to 65 years (OR 2.42; 95% CI, 1.22-4.82). Testosterone 144-156 estrogen receptor 1 Homo sapiens 85-87 23241075-9 2012 In ER-positive group, elevated testosterone levels appeared also associated with AR-absent expression, although the small number of patients in this category limited the appearance of significant effects (OR 1.92; 95% CI, 0.73-5.02): the association was present in both age groups (<65 and >=65 years). Testosterone 31-43 estrogen receptor 1 Homo sapiens 3-5 23241075-10 2012 In the ER-negative group, elevated testosterone levels were found associated (borderline significance) with AR-absent expression (OR 2.82, 95% CI, 0.98-8.06). Testosterone 35-47 estrogen receptor 1 Homo sapiens 7-9 23241075-11 2012 In this ER-negative/AR-absent subset of tumors, elevated testosterone levels cannot stimulate cancer growth either directly or after conversion into estrogens, but they probably induce increased synthesis of some other substance that is responsible for cancer growth through binding to its specific receptor. Testosterone 57-69 estrogen receptor 1 Homo sapiens 8-10 20200813-11 2012 Furthermore, a synergistic effect of ESR1 and ESR2 genes is exerted on serum testosterone levels. Testosterone 79-91 estrogen receptor 1 Homo sapiens 38-42 22180173-9 2011 Mean testosterone levels were higher in ER-positive than ER-negative patients (p and <0.001), while mean estradiol levels did not differ significantly between the two ER categories (p=0.192). Testosterone 5-17 estrogen receptor 1 Homo sapiens 40-42 22180173-10 2011 The ORs of having an ER-positive tumor increased significantly with increasing quartiles of testosterone (Ptrend=0.002), whereas the increase with increasing estradiol quartiles was not significant (Ptrend=0.07). Testosterone 92-104 estrogen receptor 1 Homo sapiens 21-23 22180173-12 2011 The strong association of testosterone with ER contrasts with the weak association of estradiol with ER and confirms testosterone as a marker of hormone-dependent tumors. Testosterone 26-38 estrogen receptor 1 Homo sapiens 44-46 20619266-6 2011 Since testosterone induces brain masculinization through its aromatization to estradiol in a narrow time window of the perinatal stage in rodents, the autoregulation of estrogen receptors, especially the predominant form of ERalpha, at the level of DNA methylation to set up the "cell memory" affecting the sexually differentiated status of brain function has been attracting increasing attention. Testosterone 6-18 estrogen receptor 1 Homo sapiens 224-231 21330633-7 2011 RESULT: The unadjusted absolute rates of ER-negative breast cancer for testosterone quartiles 1-4 were 0.34, 0.20, 0.23, and 0.21 per 10,000 person-years, respectively. Testosterone 71-83 estrogen receptor 1 Homo sapiens 41-43 21330633-10 2011 ER-positive breast cancer risk increased with higher testosterone levels (P(trend) = .04), but this trend was not statistically significant after adjustment for estradiol (P(trend) = .15). Testosterone 53-65 estrogen receptor 1 Homo sapiens 0-2 21330633-12 2011 CONCLUSION: Higher serum levels of bioavailable testosterone are associated with lower risks of ER-negative breast cancer in postmenopausal women. Testosterone 48-60 estrogen receptor 1 Homo sapiens 96-98 12851512-7 2003 Testosterone reduces mammary epithelial estrogen receptor (ER) alpha and increases ERbeta expression, resulting in a marked reversal of the ERalpha/beta ratio found in the estrogen-treated monkey. Testosterone 0-12 estrogen receptor 1 Homo sapiens 40-68 21941679-12 2011 Taken together, both human and animal studies suggest that testosterone has a dual mode of action on different bone surfaces with involvement of both the androgen and estrogen receptor. Testosterone 59-71 estrogen receptor 1 Homo sapiens 167-184 21442976-19 2010 Preclinical data concerning the role of androgens in the ADHD pathogenesis suggest that the elevated testosterone level can diminish the brain blood flow in the frontal cortex, via lowering of the level of estrogen receptor-alpha and the vascular endothelial growth factor (VEGF), and in consequence disturb processes of the memory. Testosterone 101-113 estrogen receptor 1 Homo sapiens 206-229 19843675-7 2009 ORs of having estrogen receptor- and progesterone receptor-negative versus estrogen receptor- and progesterone receptor-positive tumors decreased significantly with increasing testosterone tertiles. Testosterone 176-188 estrogen receptor 1 Homo sapiens 14-31 19843675-7 2009 ORs of having estrogen receptor- and progesterone receptor-negative versus estrogen receptor- and progesterone receptor-positive tumors decreased significantly with increasing testosterone tertiles. Testosterone 176-188 estrogen receptor 1 Homo sapiens 75-92 19574343-4 2009 Further noteworthy novel findings were observed between SNPs in ESR1 with testosterone levels (rs722208, mean difference = 8.8%, P = 7.37 x 10(-6)) and SRD5A2 with 3 alpha-androstanediol-glucuronide (rs2208532, mean difference = 11.8%, P = 1.82 x 10(-6)). Testosterone 74-86 estrogen receptor 1 Homo sapiens 64-68 19775474-0 2009 A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells. Testosterone 49-61 estrogen receptor 1 Homo sapiens 19-27 19775474-4 2009 The aim of the present study was to investigate the role of ER-alpha36 in testosterone carcinogenesis. Testosterone 74-86 estrogen receptor 1 Homo sapiens 60-68 19775474-9 2009 Testosterone induced ERK and Akt phosphorylation, which could be abrogated by ER-alpha 36 shRNA knockdown or the kinase inhibitors, U0126 and LY294002, and the aromatase inhibitor letrozole. Testosterone 0-12 estrogen receptor 1 Homo sapiens 78-86 18593825-10 2008 Carriers of a "TA" haplotype of the estrogen receptor alpha gene (ER alpha) PvuII and XbaI polymorphisms displayed a slower decline of TT and BioT (P=0.041-0.007). Testosterone 135-137 estrogen receptor 1 Homo sapiens 36-59 18593825-10 2008 Carriers of a "TA" haplotype of the estrogen receptor alpha gene (ER alpha) PvuII and XbaI polymorphisms displayed a slower decline of TT and BioT (P=0.041-0.007). Testosterone 135-137 estrogen receptor 1 Homo sapiens 66-74 18445666-2 2008 Several studies have detected associations between variations in genes encoding estrogen receptors alpha (ESR1) and beta (ESR2), and enzyme aromatase (CYP19A1), which regulates the estrogen to testosterone ratio, and cardiovascular phenotypes in the Framingham Heart Study. Testosterone 193-205 estrogen receptor 1 Homo sapiens 106-110 18252198-4 2008 In MCF-7 cells, which predominantly express ER-alpha, 17beta-estradiol and testosterone dose-dependently decreased OPG mRNA levels and protein secretion by 70 and 65%, respectively (p<0.0001 by ANOVA). Testosterone 75-87 estrogen receptor 1 Homo sapiens 44-52 17823853-8 2008 However, testosterone together with 17beta-estradiol (E2) increased BCRP protein and mRNA approximately twofold, and this induction was abolished by ICI-182,780 or the testosterone receptor (TR) antagonist flutamide or knock-down of ER alpha expression. Testosterone 9-21 estrogen receptor 1 Homo sapiens 233-241 17158782-6 2007 ER alpha-null follicles also exhibited increased testosterone synthesis due to ectopic expression of hydroxysteroid (17beta) dehydrogenase type 3 (HSD17B3), a testis-specific androgenic enzyme. Testosterone 49-61 estrogen receptor 1 Homo sapiens 0-8 19775474-10 2009 CONCLUSION: Testosterone induces ERK and Akt phosphorylation via the membrane-initiated signaling pathways mediated by ER-alpha36, suggesting a possible involvement of ER-alpha 36 in testosterone carcinogenesis. Testosterone 12-24 estrogen receptor 1 Homo sapiens 119-127 16782420-0 2006 Estrogen receptor alpha genotype confers interindividual variability of response to estrogen and testosterone in mesenchymal-stem-cell-derived osteoblasts. Testosterone 97-109 estrogen receptor 1 Homo sapiens 0-23 16773200-5 2006 Significant associations were also found between the highest and the lowest quartiles of testosterone, resulting in OR=4.1 (95% CI: 1.8-9.4) for the risks of breast cancer and OR=5.8 (96% CI: 2.1-16.2) of ER+PR+ breast cancer. Testosterone 89-101 estrogen receptor 1 Homo sapiens 205-207 16773200-11 2006 The increased prevalence of ER+ breast cancers in patients with higher levels of IGF-I, IGFBP-3 or testosterone implicate these hormones in the etiology of hormone-dependent breast cancer. Testosterone 99-111 estrogen receptor 1 Homo sapiens 28-30 15033428-0 2004 Sexually dimorphic regulation of estrogen receptor alpha mRNA in the ventromedial hypothalamus of adult whiptail lizards is testosterone dependent. Testosterone 124-136 estrogen receptor 1 Homo sapiens 33-56 15033428-7 2004 Chronic testosterone treatment reduced estrogen-induced ER alpha mRNA levels (number of grains per cell) in the VMH in females. Testosterone 8-20 estrogen receptor 1 Homo sapiens 56-64 15033428-9 2004 The abundance of estrogen-induced ER alpha mRNA in the VMH, therefore, appears to be responsive to testosterone environment in the female but not in the male, suggesting a difference in this species between the sexes in the mechanism of steroid receptor regulation. Testosterone 99-111 estrogen receptor 1 Homo sapiens 34-42 12851512-7 2003 Testosterone reduces mammary epithelial estrogen receptor (ER) alpha and increases ERbeta expression, resulting in a marked reversal of the ERalpha/beta ratio found in the estrogen-treated monkey. Testosterone 0-12 estrogen receptor 1 Homo sapiens 140-147 12012621-7 2002 In the estrogen receptor (ER)-negative cell lines BT-20 and MDA-MB 435S, testosterone was a more potent inhibitor of cell proliferation than DHT (p < or = 0.05), in contrast to the ER-positive cells lines MCF-7 and T47-D, in which a stronger inhibition of proliferation was achieved by DHT. Testosterone 73-85 estrogen receptor 1 Homo sapiens 7-24 12012621-7 2002 In the estrogen receptor (ER)-negative cell lines BT-20 and MDA-MB 435S, testosterone was a more potent inhibitor of cell proliferation than DHT (p < or = 0.05), in contrast to the ER-positive cells lines MCF-7 and T47-D, in which a stronger inhibition of proliferation was achieved by DHT. Testosterone 73-85 estrogen receptor 1 Homo sapiens 26-28 12054912-5 2002 Therefore, the aim of this study was to determine in whole DU-145 human prostate cells the effect of EFAs and their metabolites on the binding and affinity of the estrogen receptor (ER) and androgen receptor (AR) to estradiol (E(2)) and testosterone (T), respectively. Testosterone 237-249 estrogen receptor 1 Homo sapiens 163-180 12054912-5 2002 Therefore, the aim of this study was to determine in whole DU-145 human prostate cells the effect of EFAs and their metabolites on the binding and affinity of the estrogen receptor (ER) and androgen receptor (AR) to estradiol (E(2)) and testosterone (T), respectively. Testosterone 237-249 estrogen receptor 1 Homo sapiens 182-184 11403894-9 2001 In particular, taking in account their prevalent origin from testosterone aromatization at tissue and peripheral levels the presence and the distribution of the two receptors (ERalpha and ERbeta) are responsible for different responses in physiological and pathological conditions. Testosterone 61-73 estrogen receptor 1 Homo sapiens 176-183 10519397-6 1999 Transactivation assays with transfected ER-alpha reporter genes reveal a direct activation of ER-alpha by dehydroepiandrosterone (DHEA), 5alpha-androstene-3beta,17beta-diol, testosterone, and the two nonaromatizable androgens, dihydrotestosterone and 5alpha-androstane-3beta,17beta-diol. Testosterone 174-186 estrogen receptor 1 Homo sapiens 40-48 10519397-6 1999 Transactivation assays with transfected ER-alpha reporter genes reveal a direct activation of ER-alpha by dehydroepiandrosterone (DHEA), 5alpha-androstene-3beta,17beta-diol, testosterone, and the two nonaromatizable androgens, dihydrotestosterone and 5alpha-androstane-3beta,17beta-diol. Testosterone 174-186 estrogen receptor 1 Homo sapiens 94-102